CONTEXTVISION AB |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.1 NOK | 0.00% |
|
-8.68% | -20.78% |
| Apr. 03 | ContextVision Announces New Image Quality Advancements in X-Ray | CI |
| Feb. 16 | Transcript : ContextVision AB, Q4 2023 Earnings Call, Feb 16, 2024 |
| Sales 2024 * | 136M 12.43M | Sales 2025 * | 142M 12.99M | Capitalization | 472M 43.03M |
|---|---|---|---|---|---|
| Net income 2024 * | 23M 2.1M | Net income 2025 * | 24M 2.19M | EV / Sales 2024 * | 3.08 x |
| Net cash position 2024 * | 51.78M 4.72M | Net cash position 2025 * | 46.39M 4.23M | EV / Sales 2025 * | 2.99 x |
| P/E ratio 2024 * |
20
x | P/E ratio 2025 * |
19.4
x | Employees | 40 |
| Yield 2024 * |
6.67% | Yield 2025 * |
7.51% | Free-Float | 34.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on ContextVision AB
More press releases
| 1 week | -8.68% | ||
| Current month | -10.29% | ||
| 1 month | -4.69% | ||
| 3 months | -28.57% | ||
| 6 months | -21.39% | ||
| Current year | -20.78% |
1 week
5.94
6.68
1 month
5.946.98
Current year
5.949.20
1 year
5.949.88
3 years
5.9427.10
5 years
5.0530.90
10 years
1.4430.90
| Managers | Title | Age | Since |
|---|---|---|---|
Gerald Pötzsch
CEO | Chief Executive Officer | 52 | 22-07-31 |
| Director of Finance/CFO | - | 23-08-27 | |
Gunnar Läthén
CTO | Chief Tech/Sci/R&D Officer | - | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Martin Hedlund
FOU | Founder | 72 | 82-12-31 |
Lars Olof Sandèn
CHM | Chairman | 62 | 21-05-04 |
| Founder | 70 | 82-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 6.1 | 0.00% | 9,670 |
| 24-04-23 | 6.1 | -0.65% | 58,849 |
| 24-04-22 | 6.14 | -2.54% | 84,618 |
| 24-04-19 | 6.3 | -1.56% | 41,502 |
| 24-04-18 | 6.4 | -4.19% | 89,050 |
Real-time Oslo Bors, April 24, 2024 at 10:45 am EDT
More quotes
ContextVision AB is a Sweden-based medical technology software company specialized in image analysis and artificial intelligence. The Company is engaged in the image enhancement market and is a partner to the manufacturers of ultrasound, X-ray and Magnetic Resonance Imaging (MRI) equipment around the world. The Company develops software products, based on proprietary technology and artificial intelligence for image-based applications. ContextVisionâs cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The Company operates through two separate segments: the Business Unit Medical Imaging and the Business Unit Digital Pathology. ContextVision has two subsidiaries: Inify Laboratories AB og ContextVision Inc.
Calendar
2024-05-08
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
6.1
NOK
Average target price
7.5
NOK
Spread / Average Target
+22.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.78% | 42.91M | |
| +4.16% | 32.41B | |
| +12.62% | 7.31B | |
| +20.49% | 3.85B | |
| -11.41% | 3.33B | |
| -27.11% | 1.26B | |
| -34.31% | 1.12B | |
| +4.25% | 932M | |
| -23.45% | 864M | |
| -38.17% | 863M |
- Stock Market
- Equities
- CONTX Stock
